JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3007 ABT-263 (Navitoclax)
15 Citation

Target: Bcl-2|Bcl-w

Summary: Potent Bcl-2 family inhibitor, inhibits Bcl-2, Bcl-xL, and Bcl-w

≥48.73 mg/mL
A4234 TW-37
1 Citation

Target: Bcl-2|Bcl-xl|Mcl-1

Summary: Bcl-2 inhibitor, inhibits Bcl-2,Bcl-XL and Mcl-1

insoluble in H2O; ≥19.75 mg/mL
A4194 Obatoclax mesylate (GX15-070)
1 Citation

Target: Bcl-2

Summary: Potent Bcl-2 inhibitor

insoluble in H2O; ≥20.7 mg/mL
A4200 Apogossypolone (ApoG2)
2 Citation

Target: Bcl-2|Bcl-xl|Mcl-1

Summary: Bcl-2 inhibitor,nonpeptidic small molecule

≥24.55 mg/mL
A4199 Sabutoclax
2 Citation

Target: Bcl-2|Mcl-1|Bfl-1

Summary: pan-Bcl-2 inhibitor

insoluble in H2O; ≥205.6 mg/mL
A4461 Bax inhibitor peptide V5

Target: Bax

Summary: Bax inhibitor

≥29.35 mg/mL
B4881 UMI-77
1 Citation

Target: Mcl-1

Summary: Mcl-1 inhibitor, novel

≥23.4 mg/mL
B4902 (+)-Apogossypol

Target: Bcl-2

Summary: inhibitor of Bcl-2 family proteins

insoluble in H2O; ≥16.2 mg/mL
B5846 Radotinib(IY-5511)

Target: PDGFR|Bcr-Abl

Summary: Bcr-Abl tyrosine kinase inhibitor

≥13.73 mg/mL
B5978 BDA-366

Target: Bcl-2

Summary: Selective antagonist of BCL2 BH4 domain

≥50.4 mg/mL